Xiaotian Han1,2, Yechen Lu3, Xiaoqi Li1,2, Lingfang Xia1,2, Hao Wen1,2, Zheng Feng1,2, Xingzhu Ju1,2, Xiaojun Chen1,2, Xiaohua Wu1,2. 1. Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. 3. Wound Repair Center, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.
Abstract
BACKGROUND: Epithelial ovarian cancer (EOC) is the main subtype of ovarian cancer and shows an aggressive phenotype and poor prognosis. Neuronal pentraxin II (NPTX2) is a member of the neuronal pentraxin family and plays a contradictory role in different tumors. However, there has been no report about the possible role and effect of NPTX2 in EOC. METHODS: Bioinformatics analysis, qPCR, western blotting and immunohistochemistry were used to detect the expression of NPTX2 in EOC. Lentivirus-based transfection for NPTX2 overexpression or knockdown was performed on the EOC cell lines A2780, HEY, SKOV3 and OVCAR-3. The effect of NPTX2 on the malignant phenotype of EOC was examined through methods of MTS assay, Edu assay, transwell assay, western blotting analysis, qPCR analysis, luciferase reporter assay and xenograft experiment. RESULTS: EOC tissues showed higher NPTX2 expression than the normal tissues with poor prognosis. NPTX2 overexpression can promote the proliferation, invasion, migration and tumorigenesis of EOC via IL6-JAK2/STAT3 signaling pathway. Moreover, hypoxia-inducible factor-1(HIF-1) can promote the transcription and expression of NPTX2 under the hypoxic environment. NPTX2 knockdown abolished the hypoxia-induced malignant phenotypes in ECO. CONCLUSIONS: The above results suggest that NPTX2 may play a novel role in ovarian cancer's malignant phenotype and act as a promising treatment target for EOC molecular therapy.
BACKGROUND: Epithelial ovarian cancer (EOC) is the main subtype of ovarian cancer and shows an aggressive phenotype and poor prognosis. Neuronal pentraxin II (NPTX2) is a member of the neuronal pentraxin family and plays a contradictory role in different tumors. However, there has been no report about the possible role and effect of NPTX2 in EOC. METHODS: Bioinformatics analysis, qPCR, western blotting and immunohistochemistry were used to detect the expression of NPTX2 in EOC. Lentivirus-based transfection for NPTX2 overexpression or knockdown was performed on the EOC cell lines A2780, HEY, SKOV3 and OVCAR-3. The effect of NPTX2 on the malignant phenotype of EOC was examined through methods of MTS assay, Edu assay, transwell assay, western blotting analysis, qPCR analysis, luciferase reporter assay and xenograft experiment. RESULTS: EOC tissues showed higher NPTX2 expression than the normal tissues with poor prognosis. NPTX2 overexpression can promote the proliferation, invasion, migration and tumorigenesis of EOC via IL6-JAK2/STAT3 signaling pathway. Moreover, hypoxia-inducible factor-1(HIF-1) can promote the transcription and expression of NPTX2 under the hypoxic environment. NPTX2 knockdown abolished the hypoxia-induced malignant phenotypes in ECO. CONCLUSIONS: The above results suggest that NPTX2 may play a novel role in ovarian cancer's malignant phenotype and act as a promising treatment target for EOC molecular therapy.
Authors: Lisa Bjartmar; Andrew D Huberman; Erik M Ullian; René C Rentería; Xiaoqin Liu; Weifeng Xu; Jennifer Prezioso; Michael W Susman; David Stellwagen; Caleb C Stokes; Richard Cho; Paul Worley; Robert C Malenka; Sherry Ball; Neal S Peachey; David Copenhagen; Barbara Chapman; Masaru Nakamoto; Ben A Barres; Mark S Perin Journal: J Neurosci Date: 2006-06-07 Impact factor: 6.167
Authors: Michelle R Jones; Pei-Chen Peng; Simon G Coetzee; Jonathan Tyrer; Alberto Luiz P Reyes; Rosario I Corona; Brian Davis; Stephanie Chen; Felipe Dezem; Ji-Heui Seo; Siddartha Kar; Eileen Dareng; Benjamin P Berman; Matthew L Freedman; Jasmine T Plummer; Kate Lawrenson; Paul Pharoah; Dennis J Hazelett; Simon A Gayther Journal: Am J Hum Genet Date: 2020-09-17 Impact factor: 11.025
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Linda B Moran; Lorraine Hickey; Gregory J Michael; Maria Derkacs; Lynne M Christian; Michail E Kalaitzakis; Ronald K B Pearce; Manuel B Graeber Journal: Acta Neuropathol Date: 2007-11-07 Impact factor: 17.088